Gilead Shines Some Light On Its Inflammation Ambitions

Part Of Ongoing Diversification Strategy

 
• By Mandy Jackson

CEO Daniel O’Day and EVP-research Flavius Martin highlighted Gilead’s inflammation R&D and dealmaking focus at the recent J.P. Morgan meeting.

Gilead announced a new deal and reworked an old deal in inflammation already this year (Shutterstock)

More from Strategy

More from Scrip